Ignite Creation Date:
2024-05-06 @ 9:34 AM
Last Modification Date:
2024-10-26 @ 12:16 PM
Study NCT ID:
NCT03010527
Status:
COMPLETED
Last Update Posted:
2022-10-18
First Post:
2017-01-03
Brief Title:
A Study to Evaluate the Long-term Safety Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
A Multicenter 48-Week Double-Blind Placebo-Controlled Parallel-Group Extension Study to Assess the Long-Term Safety Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BE ABLE 2
Brief Summary:
This is a multicenter extension study to assess the long-term safety tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2016-001892-57 | EUDRACT_NUMBER | None | None |